COVID Update: Recalibrating the Vaccine Rollout in Light of new Clotting Cases

Healthed

writer

Healthed

Healthed

Over the past 72 hours, three more Australian cases of clotting that appear to be connected to the AZ vaccine have been reported. Patients are obviously very concerned and this is leading to many queries at clinics and increased hesitancy.

The condition – known as vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) looks similar to heparin-induced thrombocytopenia, causing clotting in various parts of the body.

Generally it occurs 4-20 days after the first dose of the AstraZeneca vaccine. No cases have occurred after the second dose.

The Covid vaccine programme has recently changed in line with these developments and current target dates for our vaccine rollout have needed to be recalibrated in light of new vaccine recommendations for people under age 50 to have the Pfizer vaccine. For patients having the AstraZeneca vaccine, new consent forms include questions about history of thrombosis and thrombocytopenia.

Learn about these and other important developments in the upcoming Healthed webcast featuring Associate Professor Nicholas Wood from the National Centre for Research and Surveillance.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
A/Prof William Kemp

A/Prof William Kemp

Cardiovascular Risk and Fatty Liver Disease

Dr Ryan De Cruz

Dr Ryan De Cruz

Importance of Early & Effective Treatment of Mild to Moderate Acne

Prof Merlin Thomas

Prof Merlin Thomas

SGLT2s and Renal Protection

Dr Adam Nelson

Dr Adam Nelson

CV Medications – Practical Strategies to Improve Compliance

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.

Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.

Upcoming Healthed Webcast

Cardiovascular Risk and Fatty Liver Disease

Tuesday 11th November, 7pm - 9pm AEDT

Speaker

A/Prof William Kemp

Gastroenterologist and Hepatologist; Alfred Hospital Melbourne, Monash University School of Translational Medicine

We invite you to our next free webcast, where I will discuss cardiovascular risk and fatty liver disease. Earn up to 4 hours CPD. RACGP & ACRRM accredited.